Sasank C Kunadharaju

US Patent:

20190029979, Jan 31, 2019

Filed:

Jan 23, 2017

Appl. No.:

16/075745

Inventors:

- New York NY, US
Tushar MALKAN - Dayton NJ, US
Sasank KUNADHARAJU - Edison NJ, US
Satish PEJAVER - Bridgewater NJ, US

International Classification:

A61K 31/167
A61K 9/08
A61K 9/00
A61K 47/02
A61K 47/12
A61L 2/00

Abstract:

A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.

US Patent:

20170035774, Feb 9, 2017

Filed:

Oct 25, 2016

Appl. No.:

15/333529

Inventors:

- New York NY, US
Shyamprasad Mukundan - Parsippany NJ, US
Sasank Chaitanya Kunadharaju - Edison NJ, US
Tushar Hingorani - Piscataway NJ, US
Kumaresh Soppimath - Monmouth Junction NJ, US
Satish Pejaver - Bridgewater NJ, US
Navneet Puri - Bridgewater NJ, US

International Classification:

A61K 31/5377
A61K 9/10
A61K 47/20
A61K 47/12
A61K 9/00
A61K 47/38

Abstract:

A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

US Patent:

20150099004, Apr 9, 2015

Filed:

Oct 8, 2014

Appl. No.:

14/509964

Inventors:

- Piscataway NJ, US
Shyamprasad Mukundan - Parsippany NJ, US
Sasank Chaitanya Kunadharaju - Edison NJ, US
Tushar Hingorani - Piscataway NJ, US
Kumaresh Soppimath - Monmouth Junction NJ, US
Satish Pejaver - Bridgewater NJ, US
Navneet Puri - Bridgewater NJ, US

International Classification:

A61K 31/5377
A61K 9/10
A61K 47/20
A61K 9/00
A61K 9/14
A61K 47/38

US Classification:

424499, 5142362

Abstract:

A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.